Want to see JP:4563 full AI Analyst Report?

AnGes (4563) Price & Analysis

1 Followers

4563 Stock Chart & Stats

¥47.00

¥0.00(0.00%)

At close: Jul 27 4:00 PM EDT

¥47.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥37.00 - ¥120.00

Previous CloseN/A

Volume237.70K

Average Volume (3M)3.22M

Market Cap

¥15.55B

Enterprise Value¥19.10K

Total Cash (Recent Filing)¥835.88M

Total Debt (Recent Filing)¥688.34M

Price to Earnings (P/E)―

Beta0.89

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-14.10

Shares Outstanding398,835,540

10 Day Avg. Volume1,701,110

30 Day Avg. Volume3,216,076

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)7.04

Price to Sales (P/S)24.76

P/FCF Ratio-3.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improving Revenue MomentumMeaningful revenue acceleration indicates stronger commercialization or collaboration activity. If sustained, higher sales and partnership income could improve operating leverage and provide a broader base for funding the biotechnology pipeline.

Low Financial LeverageLimited debt reduces fixed financing obligations and preserves flexibility while AnGes funds research and development. This gives the company more capacity to pursue programs or partnerships without immediate pressure from substantial creditor claims.

Specialized Gene-Medicine PlatformA focused position in gene-based therapeutics gives AnGes exposure to a specialized healthcare area with potential for product, licensing, milestone, and royalty income. Successful development or partnering could create scalable recurring value.

Bears Say

Persistent Operating LossesContinuing operating and net losses show that revenue growth has not yet produced a sustainable earnings model. Until products or collaborations generate sufficient gross profit, profitability remains dependent on uncertain pipeline execution.

Deeply Negative Cash GenerationPersistent cash consumption limits the company’s ability to self-fund clinical, regulatory, and commercial activities. Continued burn may require external financing or asset resources, creating dilution and execution risk over the medium term.

Eroding Balance Sheet And Funding DependenceDeclining assets and equity indicate that cumulative losses are weakening financial resilience despite low debt. This reduces the buffer available for setbacks and increases dependence on successful financing, partnerships, or commercialization.

4563 FAQ

What was AnGes Inc’s price range in the past 12 months?

AnGes Inc lowest stock price was ¥37.00 and its highest was ¥120.00 in the past 12 months.

What is AnGes Inc’s market cap?

AnGes Inc’s market cap is ¥15.55B.

When is AnGes Inc’s upcoming earnings report date?

AnGes Inc’s upcoming earnings report date is Nov 06, 2026 which is in 73 days.

How were AnGes Inc’s earnings last quarter?

AnGes Inc released its earnings results on Aug 07, 2026. The company reported -¥4.11 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is AnGes Inc overvalued?

According to Wall Street analysts AnGes Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AnGes Inc pay dividends?

AnGes Inc does not currently pay dividends.

What is AnGes Inc’s EPS estimate?

AnGes Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AnGes Inc have?

AnGes Inc has 398,835,540 shares outstanding.

What happened to AnGes Inc’s price movement after its last earnings report?

AnGes Inc reported an EPS of -¥4.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.041%.

Which hedge fund is a major shareholder of AnGes Inc?

Currently, no hedge funds are holding shares in JP:4563

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AnGes Inc

AnGes, Inc. (4563) is a Japanese biotechnology company focused on developing and commercializing nucleic-acid–based medicines and gene therapies. The company’s activities center on research and development, clinical development, regulatory work, and potential out-licensing of drug candidates, with a portfolio historically associated with DNA plasmid–based therapeutics and other genetic medicine approaches. null